

Manuela Iezzi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5409191/manuela-iezzi-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110 papers	4,125 citations	34 h-index	59 g-index
116 ext. papers	4,767 ext. citations	7.3 avg, IF	4.65 L-index

#	Paper	IF	Citations
110	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. 2022 , 10,		3
109	Deciphering the state of immune silence in fatal COVID-19 patients. <i>Nature Communications</i> , 2021 , 12, 1428	17.4	34
108	Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages. <i>FASEB Journal</i> , 2021 , 35, e21441	0.9	15
107	Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study. <i>Journal of Translational Medicine</i> , 2021 , 19, 24	8.5	7
106	Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2021 , 9, 1316-1326	12.5	5
105	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. <i>Cell Death and Differentiation</i> , 2021 ,	12.7	4
104	Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis. <i>Frontiers in Immunology</i> , 2020 , 11, 581	8.4	28
103	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
102	Baricitinib restrains the immune dysregulation in patients with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6409-6416	15.9	130
101	Repurposing a psychoactive drug for children with cancer: p27-dependent inhibition of metastatic neuroblastomas by Prozac. <i>Oncogenesis</i> , 2020 , 9, 3	6.6	4
100	Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2975-2989	9.4	76
99	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. <i>Cancers</i> , 2020 , 12,	6.6	6
98	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. <i>Cancer Discovery</i> , 2020 , 10, 1758-1773	24.4	17
97	Pyruvium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism. <i>Cancer Research</i> , 2020 , 80, 4087-4102	10.1	13
96	The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. <i>Cell Death and Differentiation</i> , 2020 , 27, 790-807	12.7	9
95	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019 , 42, 815-828	7.2	9
94	PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. <i>BMC Cancer</i> , 2019 , 19, 747	4.8	17

93	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 5612-5625	10.1	8
92	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 658-670	12.5	21
91	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. <i>Journal of Controlled Release</i> , 2018 , 277, 48-56	11.7	16
90	MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. <i>Cell Death and Disease</i> , 2018 , 9, 821	9.8	18
89	Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer. <i>Scientific Reports</i> , 2018 , 8, 10567	4.9	5
88	In vitro and in vivo studies of gold(II) azolate/phosphane complexes for the treatment of basal like breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2018 , 155, 418-427	6.8	12
87	Efficacy and Safety of Lycoprozen [®] , a Novel Tomato-Based Food Supplement in Patients with Benign Prostatic Hyperplasia. <i>International Journal of Nutrition</i> , 2018 , 3, 1-5	2.2	3
86	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018 , 9, 5193	17.4	31
85	Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. <i>Cancer Immunology Research</i> , 2018 , 6, 1486-1498	12.5	13
84	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. <i>Nature Communications</i> , 2017 , 8, 14797	17.4	12
83	EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. <i>Oncotarget</i> , 2017 , 8, 95412-95424	3.3	17
82	Resveratrol has anti-thyroid effects both in vitro and in vivo. <i>Food and Chemical Toxicology</i> , 2017 , 107, 237-247	4.7	30
81	Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. <i>Journal of Pathology</i> , 2017 , 241, 350-361	9.4	49
80	Resveratrol fuels HER2 and ER α -positive breast cancer behaving as proteasome inhibitor. <i>Aging</i> , 2017 , 9, 508-523	5.6	32
79	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017 , 8, 54444-54458	3.3	10
78	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. <i>Oncotarget</i> , 2017 , 8, 86987-87001	3.3	13
77	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. <i>Oncolmunology</i> , 2016 , 5, e1253653	7.2	18
76	ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 487-95	8.9	102

75	Class II phosphoinositide 3-kinase C2 β regulates a novel signaling pathway involved in breast cancer progression. <i>Oncotarget</i> , 2016 , 7, 18325-45	3.3	16
74	Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. <i>Oncotarget</i> , 2016 , 7, 58743-58758	3.3	26
73	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. <i>Cancer Research</i> , 2016 , 76, 2540-51	10.1	21
72	The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5-dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. <i>Pharmacological Research</i> , 2016 , 107, 282-290	10.2	43
71	Irreversible inhibition of β 6HER2 is necessary to suppress β 6HER2-positive breast carcinomas resistant to Lapatinib. <i>Cancer Letters</i> , 2016 , 381, 76-84	9.9	18
70	Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 745-51	8.9	22
69	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. <i>Oncolimmunology</i> , 2015 , 4, e1005500	7.2	9
68	Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor. <i>Journal of Immunology Research</i> , 2015 , 2015, 159145	4.5	10
67	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015 , 17, 70	8.3	10
66	Effect of maternal exposure to endocrine disrupting chemicals on reproduction and mammary gland development in female Sprague-Dawley rats. <i>Reproductive Toxicology</i> , 2015 , 54, 110-9	3.4	27
65	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014 , 16, R10	8.3	25
64	Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. <i>Clinical Lung Cancer</i> , 2014 , 15, 470-479	4.9	12
63	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014 , 15 Suppl 3, S1	4.5	17
62	Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. <i>Biochemical Pharmacology</i> , 2014 , 90, 226-34	6	47
61	Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 2026-31	8.9	11
60	rBet v 1 immunotherapy of sensitized mice with Streptococcus thermophilus as vehicle and adjuvant. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 1228-37	4.4	5
59	Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. <i>Journal of Immunology</i> , 2014 , 192, 5434-41	5.3	14
58	Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. <i>Cancer Research</i> , 2014 , 74, 6248-59	10.1	47

57	Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding α B integrins. <i>Contrast Media and Molecular Imaging</i> , 2013 , 8, 350-60	3.2	9
56	HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies 2013 ,		2
55	Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. <i>PLoS Pathogens</i> , 2013 , 9, e1003155	7.6	27
54	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. <i>Onc Immunology</i> , 2013 , 2, e26137	7.2	21
53	Expression of CREB in primary pterygium and correlation with cyclin D1, ki-67, MMP7, p53, p63, Survivin and Vimentin. <i>Ophthalmic Research</i> , 2013 , 50, 99-107	2.9	14
52	HER-2/neu mediates oncogenic transformation via altered CREB expression and function. <i>Molecular Cancer Research</i> , 2013 , 11, 1462-77	6.6	25
51	p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. <i>Breast Cancer Research</i> , 2012 , 14, R137	8.3	21
50	Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. <i>PLoS ONE</i> , 2012 , 7, e39626	3.7	66
49	A vaccine targeting angiominin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. <i>Angiogenesis</i> , 2012 , 15, 305-16	10.6	33
48	DNA vaccination against oncoantigens: A promise. <i>Onc Immunology</i> , 2012 , 1, 316-325	7.2	30
47	HCG hastens both the development of mammary carcinoma and the metastatization of HCG/LH and ERBB-2 receptor-positive cells in mice. <i>International Journal of Immunopathology and Pharmacology</i> , 2011 , 24, 621-30	3	10
46	A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. <i>Cancer Prevention Research</i> , 2011 , 4, 994-1001	3.2	5
45	The human splice variant Δ 6HER2 induces rapid tumor onset in a reporter transgenic mouse. <i>PLoS ONE</i> , 2011 , 6, e18727	3.7	55
44	p130Cas is an essential transducer element in ErbB2 transformation. <i>FASEB Journal</i> , 2010 , 24, 3796-808	0.9	39
43	Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. <i>Molecular Biology of the Cell</i> , 2010 , 21, 704-11	3.5	51
42	ErbB2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. <i>Journal of Immunology</i> , 2010 , 184, 6124-32	5.3	24
41	AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010 , 25, 143-8	3.9	18
40	A better immune reaction to ErbB-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. <i>Cancer Research</i> , 2010 , 70, 2604-12	10.1	44

39	A dietary tomato supplement prevents prostate cancer in TRAMP mice. <i>Cancer Prevention Research</i> , 2010 , 3, 1284-91	3.2	33
38	Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. <i>Blood</i> , 2010 , 115, 1374-84	2.2	27
37	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 2803-15	5.6	201
36	Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. <i>PLoS ONE</i> , 2010 , 5, e14131	3.7	28
35	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009 , 27, 2065-9	4.1	1
34	Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. <i>Human Gene Therapy</i> , 2008 , 19, 229-40	4.8	18
33	Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. <i>Cancer Research</i> , 2008 , 68, 9865-74	10.1	40
32	Phospholipase Cgamma1 is required for metastasis development and progression. <i>Cancer Research</i> , 2008 , 68, 10187-96	10.1	110
31	Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. <i>Science Signaling</i> , 2008 , 1, ra3	8.8	198
30	Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. <i>Current Cancer Drug Targets</i> , 2008 , 8, 230-42	2.8	13
29	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007 , 121, 88-94	7.5	4
28	Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. <i>Cancer Research</i> , 2007 , 67, 5454-60	10.1	41
27	Antimetastatic activity of a preventive cancer vaccine. <i>Cancer Research</i> , 2007 , 67, 11037-44	10.1	42
26	Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. <i>Journal of Cellular Physiology</i> , 2006 , 207, 23-9	7	62
25	Triggering CD40 on endothelial cells contributes to tumor growth. <i>Journal of Experimental Medicine</i> , 2006 , 203, 2441-50	16.6	67
24	Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. <i>Cancer Research</i> , 2006 , 66, 7734-40	10.1	71
23	Biofilm formation by the emerging fungal pathogen <i>Trichosporon asahii</i> : development, architecture, and antifungal resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3269-76	5.9	158
22	A DNA vaccine targeting angiotensin inhibits angiogenesis and suppresses tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9208-13	11.5	66

21	Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. <i>Journal of Immunology</i> , 2006 , 176, 7695-703	5.3	19
20	Analytical assessment of MALDI-TOF Imaging Mass Spectrometry on thin histological samples. An insight in proteome investigation. <i>Clinica Chimica Acta</i> , 2005 , 357, 210-8	6.2	26
19	Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. <i>American Journal of Pathology</i> , 2005 , 166, 1205-16	5.8	41
18	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. <i>Vaccine</i> , 2005 , 23, 3280-7	4.1	16
17	An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. <i>BMC Bioinformatics</i> , 2005 , 6 Suppl 4, S7	3.6	25
16	Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. <i>International Journal of Cancer</i> , 2005 , 113, 67-77	7.5	46
15	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 599-610	7.4	12
14	Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. <i>Clinical Cancer Research</i> , 2005 , 11, 1941-52	12.9	58
13	Cutting edge: TRAIL deficiency accelerates hematological malignancies. <i>Journal of Immunology</i> , 2005 , 175, 5586-90	5.3	131
12	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 4185-90	11.5	253
11	Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. <i>Cancer Research</i> , 2005 , 65, 8339-49	10.1	116
10	Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. <i>Cancer Research</i> , 2004 , 64, 2858-64	10.1	137
9	Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. <i>Cancer Research</i> , 2004 , 64, 4001-9	10.1	79
8	Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. <i>Journal of Immunology</i> , 2004 , 173, 2288-96	5.3	87
7	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004 , 113, 709-17	15.9	58
6	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <i>International Journal of Cancer</i> , 2003 , 105, 384-9	7.5	27
5	LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. <i>Cancer Research</i> , 2003 , 63, 2518-25	10.1	62
4	Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3850-6	2.2	34

3	Neutrophils in anti-cancer immunological strategies: old players in new games. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001 , 10, 739-48		24
2	Salivary carcinoma in HER-2/neu transgenic male mice: An angiogenic switch is not required for tumor onset and progression. <i>International Journal of Cancer</i> , 2000 , 88, 329-335	7.5	13
1	Deciphering the state of immune silence in fatal COVID-19 patients		4